Literature DB >> 20350577

Altered glial-neuronal crosstalk: cornerstone in the pathogenesis of hepatic encephalopathy.

Roger F Butterworth1.   

Abstract

Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of liver failure, characterized neuropathologically by astrocyte swelling, microglial activation and Alzheimer Type II astrocytosis. Molecular studies in HE brain reveal altered expression of genes coding for key astroglial proteins including early losses of expression of GFAP and the glutamate transporter EEAT-2 with concomitant increases of the astrocytic/microglial mitochondrial benzodiazepine receptor (MBR). Decreased expression of EAAT-2 results in decreased glutamate transport and impaired cycling of glutamate-glutamine between astrocytes and neurons, as well as increased extracellular glutamate, activation of the NMDA receptor-mediated cGMP-NO signal transduction pathway, and nitration of tyrosine residues on key astroglial proteins such as glutamine synthetase (GS) and the MBR. GS is uniquely responsible for the removal of excess ammonia in brain. Ammonia-induced activation of MBR in astrocytes and/or microglia results in stimulation of the synthesis of neurosteroids such as allopregnanolone with positive allosteric GABA-A receptor neuromodulatory properties. Allopregnanolone concentrations are increased up to 7-fold in HE brain. Attenuation of microglial activation by minocycline results in a delay in onset of HE and prevents brain edema in liver failure. Mild hypothermia is likewise beneficial in acute liver failure resulting in normalization of extracellular brain glutamate and prevention of oxidative/nitrosative stress in experimental animals with HE resulting from either ischemic or toxic liver injuries. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20350577     DOI: 10.1016/j.neuint.2010.03.012

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  30 in total

Review 1.  Astrocytes in neurodegenerative disease.

Authors:  Hemali Phatnani; Tom Maniatis
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-15       Impact factor: 10.005

Review 2.  Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.

Authors:  Maria Valeria Catani; Valeria Gasperi; Tiziana Bisogno; Mauro Maccarrone
Journal:  Antioxid Redox Signal       Date:  2017-07-24       Impact factor: 8.401

Review 3.  Astrocytic regulation of glutamate homeostasis in epilepsy.

Authors:  Douglas A Coulter; Tore Eid
Journal:  Glia       Date:  2012-05-16       Impact factor: 7.452

4.  Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.

Authors:  Y Avraham; Nc Grigoriadis; T Poutahidis; L Vorobiev; I Magen; Y Ilan; R Mechoulam; Em Berry
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

5.  A zebrafish model of hyperammonemia.

Authors:  B Feldman; M Tuchman; L Caldovic
Journal:  Mol Genet Metab       Date:  2014-07-10       Impact factor: 4.797

6.  Astroglia in neurological diseases.

Authors:  Alexei Verkhratsky; José J Rodríguez; Vladimir Parpura
Journal:  Future Neurol       Date:  2013-03-01

Review 7.  Why are astrocytes important?

Authors:  Alexei Verkhratsky; Maiken Nedergaard; Leif Hertz
Journal:  Neurochem Res       Date:  2014-08-12       Impact factor: 3.996

8.  Ammonium Increases TRPC1 Expression Via Cav-1/PTEN/AKT/GSK3β Pathway.

Authors:  Wei Wang; Li Gu; Alexei Verkhratsky; Liang Peng
Journal:  Neurochem Res       Date:  2016-07-14       Impact factor: 3.996

Review 9.  Neurotoxicity of Ammonia.

Authors:  Simo S Oja; Pirjo Saransaari; Esa R Korpi
Journal:  Neurochem Res       Date:  2016-07-28       Impact factor: 3.996

10.  Comorbidities, confounders, and the white matter transcriptome in chronic alcoholism.

Authors:  Greg T Sutherland; Donna Sheedy; Pam J Sheahan; Warren Kaplan; Jillian J Kril
Journal:  Alcohol Clin Exp Res       Date:  2014-01-24       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.